Idiopathic pulmonary fibrosis
Drug Safety Update
November 2020: Pirfenidone (Esbriet): risk of serious liver injury; updated advice on liver function testing
July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
NICE guidance (see drug-specific links below)
CG163: Idiopathic pulmonary fibrosis in adults: diagnosis and management, June 2013 (last updated May 2017)
These drugs are available from specialist centres only (not MTW) and should be initiated and supervised by an appropriate specialist
| Pack | Price |
|---|---|
| 252 capsule (4 x 63 capsules) | |
| 270 capsule | |
| 63 capsule (1 x 21 caps + 1 x 42 caps) |
| Pack | Price |
|---|---|
| 252 tablet (4 x 63 tablets) | £2,007.70 |
| 63 tablet (1 x 21 tabs + 2 x 21 tabs) | £501.92 |
| Pack | Price |
|---|---|
| 84 tablet (4 x 21 tablets) | £2,007.70 |
| Pack | Price |
|---|---|
| 60 capsule (6 x 10 capsules) | £2,151.10 |
| Pack | Price |
|---|---|
| 60 capsule (6 x 10 capsules) | £2,151.10 |